These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11837613)

  • 1. A mathematical model of post-canalization thrombolysis.
    Pleydell CP; David T; Smye SW; Berridge DC
    Phys Med Biol; 2002 Jan; 47(2):209-24. PubMed ID: 11837613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a multi-physics modelling framework for thrombolysis under the influence of blood flow.
    Piebalgs A; Xu XY
    J R Soc Interface; 2015 Dec; 12(113):20150949. PubMed ID: 26655469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole blood clot dissolution: in vitro study on the effects of permeation pressure.
    Jeong WW; Jang AS; Rhee K
    Proc Inst Mech Eng H; 2007 May; 221(4):357-63. PubMed ID: 17605393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
    Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
    Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood clot dissolution dynamics simulation during thrombolytic therapy.
    Sersa I; Tratar G; Blinc A
    J Chem Inf Model; 2005; 45(6):1686-90. PubMed ID: 16309274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model.
    Meunier JM; Holland CK; Lindsell CJ; Shaw GJ
    Ultrasound Med Biol; 2007 Apr; 33(4):576-83. PubMed ID: 17337113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the effect of laminar axially directed blood flow on the dissolution of non-occlusive blood clots.
    Sersa I; Vidmar J; Grobelnik B; Mikac U; Tratar G; Blinc A
    Phys Med Biol; 2007 Jun; 52(11):2969-85. PubMed ID: 17505083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing clot lysis strategies using a simplified mathematical model.
    Smye SW; Berridge D; Ouriel K; Parkin A; David T
    J Med Eng Technol; 1997; 21(3-4):121-5. PubMed ID: 9222953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
    Zidansek A; Blinc A
    Thromb Haemost; 1991 May; 65(5):553-9. PubMed ID: 1831302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.
    Klement P; Borm A; Hirsh J; Maraganore J; Wilson G; Weitz J
    Thromb Haemost; 1992 Jul; 68(1):64-8. PubMed ID: 1514174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
    Valji K; Bookstein JJ
    Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke.
    Bednar MM; Quilley J; Russell SR; Fuller SP; Booth C; Howard D; Gross CE
    Neurosurgery; 1996 Aug; 39(2):352-9. PubMed ID: 8832673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.